99 related articles for article (PubMed ID: 18178159)
1. T cell precursor frequency differentially affects CTL responses under different immune conditions.
Ye Z; Ahmed KA; Huang J; Xie Y; Munegowda MA; Xiang J
Biochem Biophys Res Commun; 2008 Mar; 367(2):427-34. PubMed ID: 18178159
[TBL] [Abstract][Full Text] [Related]
2. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
[TBL] [Abstract][Full Text] [Related]
3. CD4+ Th2 cells function alike effector Tr1 and Th1 cells through the deletion of a single cytokine IL-6 and IL-10 gene.
Ankathatti Munegowda M; Xu S; Freywald A; Xiang J
Mol Immunol; 2012 Jun; 51(2):143-9. PubMed ID: 22424785
[TBL] [Abstract][Full Text] [Related]
4. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes.
Love VA; Grabie N; Duramad P; Stavrakis G; Sharpe A; Lichtman A
Circ Res; 2007 Aug; 101(3):248-57. PubMed ID: 17569889
[TBL] [Abstract][Full Text] [Related]
5. Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells.
Ke Y; Kapp JA
J Immunol; 1996 Feb; 156(3):916-21. PubMed ID: 8558017
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.
Waeckerle-Men Y; Starke A; Wüthrich RP
Nephrol Dial Transplant; 2007 Jun; 22(6):1527-36. PubMed ID: 17339272
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
Hao S; Bai O; Yuan J; Qureshi M; Xiang J
Cell Mol Immunol; 2006 Jun; 3(3):205-11. PubMed ID: 16893501
[TBL] [Abstract][Full Text] [Related]
8. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
9. Aspergillus fumigatus extract differentially regulates antigen-specific CD4+ and CD8+ T cell responses to promote host immunity.
Tao J; Segal BH; Eppolito C; Li Q; Dennis CG; Youn R; Shrikant PA
J Leukoc Biol; 2006 Sep; 80(3):529-37. PubMed ID: 16793916
[TBL] [Abstract][Full Text] [Related]
10. Programming of CTL with heat-killed Brucella abortus and antigen allows soluble antigen alone to generate effective secondary CTL.
Inoue S; Golding B; Scott D
Vaccine; 2005 Feb; 23(14):1730-8. PubMed ID: 15705479
[TBL] [Abstract][Full Text] [Related]
11. Breaking B-cell tolerance and CTL tolerance in three OVA-transgenic mouse strains expressing different levels of OVA.
Steinaa L; Rasmussen PB; Gautam A; Mouritsen S
Scand J Immunol; 2008 Feb; 67(2):113-20. PubMed ID: 18201366
[TBL] [Abstract][Full Text] [Related]
12. The cytotoxic T lymphocyte response against a protein antigen does not decrease the antibody response to that antigen although antigen-pulsed B cells can be targets.
Wang W; Golding B
Immunol Lett; 2005 Sep; 100(2):195-201. PubMed ID: 15916814
[TBL] [Abstract][Full Text] [Related]
13. Tumor apoptotic bodies inhibit CTL responses and antitumor immunity via membrane-bound transforming growth factor-beta1 inducing CD8+ T-cell anergy and CD4+ Tr1 cell responses.
Xie Y; Bai O; Yuan J; Chibbar R; Slattery K; Wei Y; Deng Y; Xiang J
Cancer Res; 2009 Oct; 69(19):7756-66. PubMed ID: 19789353
[TBL] [Abstract][Full Text] [Related]
14. Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10.
Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA; Abdulsamad K; Adams SL
Immunol Invest; 2008; 37(4):315-38. PubMed ID: 18569073
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of CD8+CTL responses following gene gun immunization targeting the skin with intracutaneous injection of antigen-transduced dendritic cells.
Gaffal E; Schweichel D; Tormo D; Steitz J; Lenz J; Basner-Tschakarjan E; Limmer A; Tüting T
Eur J Cell Biol; 2007 Dec; 86(11-12):817-26. PubMed ID: 16928407
[TBL] [Abstract][Full Text] [Related]
16. Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells.
Ikehara Y; Shiuchi N; Kabata-Ikehara S; Nakanishi H; Yokoyama N; Takagi H; Nagata T; Koide Y; Kuzushima K; Takahashi T; Tsujimura K; Kojima N
Cancer Lett; 2008 Feb; 260(1-2):137-45. PubMed ID: 18077084
[TBL] [Abstract][Full Text] [Related]
17. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
[TBL] [Abstract][Full Text] [Related]
18. Natural CD8⁺25⁺ regulatory T cell-secreted exosomes capable of suppressing cytotoxic T lymphocyte-mediated immunity against B16 melanoma.
Xie Y; Zhang X; Zhao T; Li W; Xiang J
Biochem Biophys Res Commun; 2013 Aug; 438(1):152-5. PubMed ID: 23876314
[TBL] [Abstract][Full Text] [Related]
19. Differential requirements of CD4(+) T-cell signals for effector cytotoxic T-lymphocyte (CTL) priming and functional memory CTL development at higher CD8(+) T-cell precursor frequency.
Umeshappa CS; Nanjundappa RH; Xie Y; Freywald A; Xu Q; Xiang J
Immunology; 2013 Apr; 138(4):298-306. PubMed ID: 23113741
[TBL] [Abstract][Full Text] [Related]
20. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
Kim TS; Lee BC; Kim E; Cho D; Cohen EP
Vaccine; 2008 Nov; 26(47):5928-34. PubMed ID: 18793691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
